Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.23.01865 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Ingo K Mellinghoff. Beteiligte Einrichtung: Former Associate Editor, Journal of Clinical Oncology, Alexandria, VA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 1 Literaturangaben. Gefördert von: NCI NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Former Associate Editor, Journal of Clinical Oncology, Alexandria, VA.
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York City, NY.
ORCID-Profile: Ingo K Mellinghoff
Förderung
- NCI NIH HHS
- NINDS NIH HHS
Zitieren
APA
Mellinghoff, I. K. (2023). Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01865
Vancouver
Mellinghoff IK. Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology. 2023. doi:10.1200/jco.23.01865
BibTeX
@article{Mellinghoff2023,
author = {Mellinghoff, Ingo K},
title = {Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.23.01865}
}
EUVIMED